Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MSC in Active Multiple Sclerosis
NCT02495766Phase 2Completed
- Sponsor
- Banc de Sang i Teixits
- Start
- May 2015
- Primary completion
- Nov 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of XCEL-MC-ALPHA in multiple sclerosis (MS) (2 arms), sponsored by Banc de Sang i Teixits. Primary endpoint: Adverse events at 12 months. Started May 2015; status: completed.
02
Drugs
XCEL-MC-ALPHA
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02495766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495766.